Voraratt Champattanachai, Ph.D.

Email: voraratt@cri.or.th

Office: Biomedical Science Building, 7th floor, Zone A

Phone: (66)2 553-8555 ext. 8347


Research Interests:

  • Human genetic diseases: inborn errors of metabolism
  • Proteomic studies and biomarker in breast and colon cancer
  • Post-translational protein modifications i.e. O-GlcNAcylation and phosphorylation
  • Cancer immunotherapy

Research information:

My research interest has been focused on abnormal proteins associated to diseases including inborn errors of metabolisms (IEMs) and cancer. IEMs are rare diseases found in children and normally result from defects in a single gene coding for an enzyme in living metabolisms. In collaboration with local pediatricians, the objective of this research is to reveal rare inborn errors of metabolisms not previously characterized in Thailand. Currently, we are exploring some rare IEMs in terms of finding their mutations, structural alternations and defective functions. They include disorders related to defects in enzymes for small molecule degradation such as methylmalonic acidemia (MMA) and diseases related to defective enzymes in large molecule digestion such as mucopolysaccharidosis (MPS), lysosomal storage diseases (LSDs) i.e. Guacher and Pompe as well as some other diseases associated with LSDs such as Parkinson’s disease.

The second project is to explore potential protein biomarkers of cancer. This research aims to identify and characterize post-translational protein modifications mainly in O-GlcNAcylation. This glycosylation is a highly dynamic and reversible process similar to protein phosphorylation. Growing evidence reveal that elevated O-GlcNAcylation is commonly found in many types of cancer. Understanding of protein O-GlcNAcylation may provide novel mechanisms of cancer development. Currently, we are trying to identify target O-GlcNAc-modified proteins which may be possible biomarkers of cancer. In addition, we are also interested in finding specific glycoprotein biomarkers in clinical liquid samples i.e. serum/plasma of patients with breast and colon cancers.

Lastly, we are interested in cancer immunotherapy. Generally, surface glycoproteins i.e. receptors on cancer cells can interact to their specific ligands presented on neighbor cells. These interactions lead to the fate of cellular functions i.e. promotion or inhibition of cancer cells. For example, blocking of CD47 on cancer cells and its ligand, SIRP-alpha enables the immune system to recognize and destroy some types Currently, we are working on the effects of CD47/SIRP-alpha blocking and other surface glycoprotein interactions in breast and colon cancer cells. We thought that if immune cells are active and recognize cancer cells, it can eliminate and kill cancer cells at the end.

Selected Publications:

  1. Elevated O-GlcNAcylation of Extracellular Vesicle Proteins Derived from Metastatic Colorectal Cancer Cells.
    Chaiyawat P, Weeraphan C, Netsirisawan P, Chokchaichamnankit D, Srisomsap C, Svasti J, Champattanachai V
    Cancer Genomics Proteomics13p387-98(2016 09-10)
  2. Analysis of Novel Mutations and Methylmalonyl-CoA Mutase Levels in Thai Patients with Isolated Methylmalonic Acidemia.
    Sawangareetrakul P, Ketudat Cairns JR, Vatanavicharn N, Liammongkolkul S, Wasant P, Svasti J, Champattanachai V
    Biochem Genetp(2015 Sep 14)
  3. Alteration of O-GlcNAcylation affects serine phosphorylation and regulates gene expression and activity of pyruvate kinase M2 in colorectal cancer cells.
    Chaiyawat P, Chokchaichamnankit D, Lirdprapamongkol K, Srisomsap C, Svasti J, Champattanachai V
    Oncol Rep34p1933-42(2015 Oct)
  4. Proteomic Analysis Reveals Aberrant O-GlcNAcylation of Extracellular Proteins from Breast Cancer Cell Secretion.
    Netsirisawan P, Chokchaichamnankit D, Srisomsap C, Svasti J, Champattanachai V
    Cancer Genomics Proteomics12p201-209(2015 07-08)
  5. Aberrant O-GlcNAcylated Proteins: New Perspectives in Breast and Colorectal Cancer.
    Chaiyawat P, Netsirisawan P, Svasti J, Champattanachai V
    Front Endocrinol (Lausanne)5p193(2014)
  6. Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer.
    Phueaouan T, Chaiyawat P, Netsirisawan P, Chokchaichamnankit D, Punyarit P, Srisomsap C, Svasti J, Champattanachai V
    Oncol Rep30p2929-36(2013 Dec)
  7. Proteomic analysis and abrogated expression of O-GlcNAcylated proteins associated with primary breast cancer.
    Champattanachai V, Netsirisawan P, Chaiyawat P, Phueaouan T, Charoenwattanasatien R, Chokchaichamnankit D, Punyarit P, Srisomsap C, Svasti J
    Proteomics13p2088-99(2013 Jul)
  8. Decreasing activity and altered protein processing of human iduronate-2-sulfatase mutations demonstrated by expression in COS7 cells.
    Charoenwattanasatien R, Cairns JR, Keeratichamroen S, Sawangareetrakul P, Tanpaiboon P, Wattanasirichaigoon D, Pangkanon S, Svasti J, Champattanachai V
    Biochem Genet50p990-7(2012 Dec)
  9. Clinical and molecular findings in Thai patients with isolated methylmalonic acidemia.
    Vatanavicharn N, Champattanachai V, Liammongkolkul S, Sawangareetrakul P, Keeratichamroen S, Ketudat Cairns JR, Srisomsap C, Sathienkijkanchai A, Shotelersuk V, Kamolsilp M, Wattanasirichaigoon D, Svasti J, Wasant P
    Mol Genet Metab106p424-9(2012 Aug)
  10. Glucosamine improves cardiac function following trauma-hemorrhage by increased protein O-GlcNAcylation and attenuation of NF-{kappa}B signaling.
    Zou L, Yang S, Champattanachai V, Hu S, Chaudry IH, Marchase RB, Chatham JC
    Am J Physiol Heart Circ Physiol296pH515-23(2009 Feb)
  11. Novel mutations found in two genes of thai patients with isolated methylmalonic acidemia.
    Keeratichamroen S, Cairns JR, Sawangareetrakul P, Liammongkolkul S, Champattanachai V, Srisomsap C, Kamolsilp M, Wasant P, Svasti J
    Biochem Genet45p421-30(2007 Jun)
  12. Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc.
    Champattanachai V, Marchase RB, Chatham JC
    Am J Physiol Cell Physiol292pC178-87(2007 Jan)
  13. The molecular basis of mucopolysaccharidosis type I in two Thai patients.
    Ketudat Cairns JR, Keeratichamroen S, Sukcharoen S, Champattanachai V, Ngiwsara L, Lirdprapamongkol K, Liammongkolkul S, Srisomsap C, Surarit R, Wasant P, Svasti J
    Southeast Asian J Trop Med Public Health36p1308-12(2005 Sep)

Full list of publications